MXPA02000880A - Metodos de tratamiento y metodos de examen de medicamentos. - Google Patents
Metodos de tratamiento y metodos de examen de medicamentos.Info
- Publication number
- MXPA02000880A MXPA02000880A MXPA02000880A MXPA02000880A MXPA02000880A MX PA02000880 A MXPA02000880 A MX PA02000880A MX PA02000880 A MXPA02000880 A MX PA02000880A MX PA02000880 A MXPA02000880 A MX PA02000880A MX PA02000880 A MXPA02000880 A MX PA02000880A
- Authority
- MX
- Mexico
- Prior art keywords
- ppar delta
- patient
- treatment
- cardiovascular diseases
- delta inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/5055—Cells of the immune system involving macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9917405.4A GB9917405D0 (en) | 1999-07-23 | 1999-07-23 | Methods of treatment and drug screening methods |
| PCT/EP2000/006986 WO2001007066A2 (en) | 1999-07-23 | 2000-07-19 | Ppar delta inhibitors for the treatment of cardiovascular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA02000880A true MXPA02000880A (es) | 2003-07-14 |
Family
ID=10857874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA02000880A MXPA02000880A (es) | 1999-07-23 | 2000-07-19 | Metodos de tratamiento y metodos de examen de medicamentos. |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP1200114B1 (es) |
| JP (1) | JP2003505058A (es) |
| KR (1) | KR20020012323A (es) |
| CN (1) | CN1364087A (es) |
| AR (1) | AR027832A1 (es) |
| AT (1) | ATE430577T1 (es) |
| AU (1) | AU6825900A (es) |
| BR (1) | BR0012661A (es) |
| CA (1) | CA2378462A1 (es) |
| CO (1) | CO5280202A1 (es) |
| CY (1) | CY1109255T1 (es) |
| CZ (1) | CZ2002247A3 (es) |
| DE (1) | DE60042161D1 (es) |
| DK (1) | DK1200114T3 (es) |
| ES (1) | ES2326785T3 (es) |
| GB (1) | GB9917405D0 (es) |
| HK (1) | HK1046094B (es) |
| HU (1) | HUP0201966A3 (es) |
| IL (1) | IL147363A0 (es) |
| MX (1) | MXPA02000880A (es) |
| MY (1) | MY140626A (es) |
| NO (1) | NO20020326L (es) |
| NZ (1) | NZ573856A (es) |
| PL (1) | PL205747B1 (es) |
| PT (1) | PT1200114E (es) |
| SI (1) | SI1200114T1 (es) |
| TR (2) | TR200200211T2 (es) |
| WO (1) | WO2001007066A2 (es) |
| ZA (1) | ZA200200542B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2417005A1 (en) * | 2000-07-20 | 2002-01-31 | Bristol Myers Squibb Company | Regulators of ppar.delta.(.beta.) and their use in the treatment of obesity and insulin resistance |
| AU2002243778A1 (en) * | 2001-02-02 | 2002-09-19 | Smithkline Beecham Corporation | Treatment of ppar mediated diseases |
| GB0103809D0 (en) | 2001-02-16 | 2001-04-04 | Univ Dundee | Methods |
| EP1511483A4 (en) * | 2002-03-27 | 2009-03-18 | Smithkline Beecham Corp | PROCESSING METHODS USING LXR MODULATORS |
| GB0302446D0 (en) * | 2003-02-03 | 2003-03-05 | Imp College Innovations Ltd | Screening for modulators of fat storage |
| US20070037882A1 (en) * | 2003-04-22 | 2007-02-15 | Astellas Pharma Inc. | Remedy for cerebral neurodegenerative diseases using ppar agonist |
| US20070237740A1 (en) * | 2004-09-27 | 2007-10-11 | Vical, Inc. | Formulations and Methods for Treatment of Inflammatory Diseases |
| DE102006033394A1 (de) * | 2006-07-13 | 2008-01-17 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Verfahren zum Auffinden von antiatherosklerotischen Substanzen |
| RU2444518C2 (ru) * | 2007-01-08 | 2012-03-10 | Сеул Нэшнл Юниверсити Индастри Фаундейшн | ПРОИЗВОДНОЕ ТИАЗОЛА КАК PPARδ ЛИГАНД И ФАРМАЦЕВТИЧЕСКИЙ, КОСМЕТИЧЕСКИЙ И ДИЕТИЧЕСКИЙ ПИЩЕВОЙ ПРОДУКТ, СОДЕРЖАЩИЙ ЕГО |
| CN112168820B (zh) * | 2019-07-05 | 2023-09-29 | 中国科学院生物物理研究所 | SRCAP ATPase抑制剂在结直肠癌治疗中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5157025A (en) * | 1991-04-01 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug |
| US5939442A (en) * | 1995-06-07 | 1999-08-17 | The Salk Institute For Biological Studies | Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof |
| WO1997028149A1 (en) * | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| CN1234029A (zh) * | 1996-08-27 | 1999-11-03 | 盐野义制药株式会社 | 色烯－3－羚酸衍生物 |
| DE69739828D1 (de) * | 1996-12-11 | 2010-05-12 | Dana Farber Cancer Inst Inc | Methoden und pharmazeutische Zusammensetzungen zur Inhibition des Tumorwachstums |
| WO1998043081A1 (en) * | 1997-03-26 | 1998-10-01 | Ligand Pharmaceuticals Incorporated | Treatment of gastrointestinal disease with ppar modulators |
| DK1016714T3 (da) * | 1997-06-27 | 2003-08-11 | Ono Pharmaceutical Co | Nyt plasmid DNA indeholdende reportergen DNA og anvendelse af samme |
| AU8355998A (en) * | 1997-07-24 | 1999-02-16 | Yamanouchi Pharmaceutical Co., Ltd. | Medicinal compositions with cholesterol-lowering effect |
| US6191154B1 (en) * | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
-
1999
- 1999-07-23 GB GBGB9917405.4A patent/GB9917405D0/en not_active Ceased
-
2000
- 2000-07-19 AU AU68259/00A patent/AU6825900A/en not_active Abandoned
- 2000-07-19 TR TR2002/00211T patent/TR200200211T2/xx unknown
- 2000-07-19 CN CN00810779A patent/CN1364087A/zh active Pending
- 2000-07-19 PT PT00956238T patent/PT1200114E/pt unknown
- 2000-07-19 IL IL14736300A patent/IL147363A0/xx unknown
- 2000-07-19 EP EP00956238A patent/EP1200114B1/en not_active Expired - Lifetime
- 2000-07-19 TR TR2005/01763T patent/TR200501763T1/xx unknown
- 2000-07-19 HU HU0201966A patent/HUP0201966A3/hu not_active Application Discontinuation
- 2000-07-19 DK DK00956238T patent/DK1200114T3/da active
- 2000-07-19 DE DE60042161T patent/DE60042161D1/de not_active Expired - Lifetime
- 2000-07-19 NZ NZ573856A patent/NZ573856A/en unknown
- 2000-07-19 ES ES00956238T patent/ES2326785T3/es not_active Expired - Lifetime
- 2000-07-19 AT AT00956238T patent/ATE430577T1/de active
- 2000-07-19 PL PL364749A patent/PL205747B1/pl not_active IP Right Cessation
- 2000-07-19 WO PCT/EP2000/006986 patent/WO2001007066A2/en not_active Application Discontinuation
- 2000-07-19 CA CA002378462A patent/CA2378462A1/en not_active Abandoned
- 2000-07-19 JP JP2001511949A patent/JP2003505058A/ja active Pending
- 2000-07-19 MX MXPA02000880A patent/MXPA02000880A/es unknown
- 2000-07-19 BR BR0012661-6A patent/BR0012661A/pt not_active Application Discontinuation
- 2000-07-19 KR KR1020027000942A patent/KR20020012323A/ko not_active Application Discontinuation
- 2000-07-19 CZ CZ2002247A patent/CZ2002247A3/cs unknown
- 2000-07-19 SI SI200031033T patent/SI1200114T1/sl unknown
- 2000-07-21 AR ARP000103776A patent/AR027832A1/es unknown
- 2000-07-21 CO CO00054777A patent/CO5280202A1/es not_active Application Discontinuation
- 2000-07-21 MY MYPI20003340A patent/MY140626A/en unknown
-
2002
- 2002-01-22 NO NO20020326A patent/NO20020326L/no not_active Application Discontinuation
- 2002-01-22 ZA ZA200200542A patent/ZA200200542B/en unknown
- 2002-10-22 HK HK02107665.7A patent/HK1046094B/zh not_active IP Right Cessation
-
2009
- 2009-07-15 CY CY20091100754T patent/CY1109255T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1999046279A3 (en) | INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE | |
| WO2005072409A3 (en) | Method and apparatus for detecting vascular conditions with a catheter | |
| WO1997019679A3 (en) | Use of nadph oxidase inhibitors for the manufacture of a medicament for prevention of atherosclerosis | |
| MEP10508A (en) | The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation | |
| MXPA03007856A (es) | Derivado de geldanamicina y metodo de usarlo para tratar cancer. | |
| PL340096A1 (en) | Methods of treating hypercoagulability states or hypoproteinaemia in respect to c protein | |
| CY1109255T1 (el) | Ppar δελτα αναστολεις για την αντιμετωπιση καρδιαγγειακων νοσων | |
| SE9702860D0 (sv) | New use | |
| SG146666A1 (en) | Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders | |
| WO2002000210A3 (en) | Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease | |
| IL165834A0 (en) | Method for treatment of indwelling catheter occlusion using fibrinolytic metalloproteinases | |
| GB9702943D0 (en) | Wound healing | |
| AU6539000A (en) | Composition and method for treating disease by increasing activated alpha2 macroglobulin in the blood and extravascular tissue | |
| WO2004037233A3 (en) | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | |
| EP1447090B8 (de) | Verwendung von Hyaluronidase zur Prophylaxe und Behandlung von Herz-Kreislauf-Erkrankungen | |
| AU2003283227A8 (en) | Method and means for the treatment of vascular and cardiac diseases | |
| IL153426A0 (en) | Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies | |
| CZ223199A3 (cs) | Použití inhibitorů COMT nebo jejich farmaceuticky vhodných solí nebo esterů pro výrobu léčiva k prevenci diabetických vaskulárních dysfunkcí | |
| DE60021111D1 (de) | Verwendung von fibrinolytischen metallproteinasen zur behandlung von blutgerinseln | |
| WO2002024144A3 (en) | Use of transcription factors for treating inflammation and other diseases | |
| WO1999043308A3 (en) | Treating pulmonary hypertension through tenascin suppression and elastase inhibition | |
| MY118982A (en) | Method of reducing tissue damage associated with ischemia | |
| EP1321146A3 (en) | Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use | |
| WO2004035030A3 (en) | Combinations of benzodithiazoles and cox-2 inhibitors for the treatment of pain | |
| UA39384A (uk) | Спосіб профілактики жовчнокам'яної хвороби |